VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
VRDN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
VRDNViridian Therapeutics, Inc.
$30.06$2.7B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksVRDNBalance Sheet

Viridian Therapeutics, Inc. (VRDN) Balance Sheet

14Y historyFree accessUpdated daily

Leverage has risen sharply, with total debt of $243.3M and a debt-to-equity ratio of 0.42 at 2026Q3 compared with 0.04 a year earlier, while the current ratio of 14.46 looks strong but must be weighed against quarterly operating outflows of roughly $90M to $125M.

Income StatementBalance SheetCash FlowRatios

VRDN Balance Sheet

Annual statement

VRDN Balance Sheet

Viridian Therapeutics, Inc. (VRDN) balance sheet — 14-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Total Current Assets1.01B894.23M738.46M486.48M424.55M200.16M129.61M29.74M65.37M51.87M4.26M11.73M6.79M2.05M1.66M
Cash & Short-Term Investments955.21M874.65M717.58M477.37M424.55M196.97M127.64M26.84M62.48M47.44M3.34M10.83M5.12M209.35K112.53K
Cash Only172.86M212.38M99.59M102.83M155.58M42.3M45.9M24.85M32.61M47.44M3.34M10.83M5.12M209.35K112.53K
Short-Term Investments782.35M662.27M617.99M374.54M268.97M154.67M81.74M2M29.88M000000
Accounts Receivable29.78M00102K102K451K0108K24K1.46M524K394K1.09M994.01K1.2M
Days Sales Outstanding363.43--118.5721.0155.56-8.841.04132.7657.3156.6691.9384.0599.04
Inventory85K000-6.62M0000064K187K179K356.64K169.54K
Days Inventory Outstanding4.2---------9.1727.6120.1552.0920.34
Other Current Assets28.06M19.58M20.88M9.01M6.52M100K0-108K2.87M2.97M170K321K050K56.21K
Total Non-Current Assets15.54M5.18M3.94M3.95M10.54M3.55M1.64M523K777K613K883K1.17M1.3M1.62M1.12M
Property, Plant & Equipment5.62M3.65M3.44M3.34M2.94M2.06M787K523K727K563K625K1.15M1.21M928.03K1.07M
Fixed Asset Turnover6.01x19.42x0.09x0.09x0.60x1.44x1.33x8.53x11.54x7.11x5.34x2.20x3.56x4.65x4.11x
Goodwill000000000000000
Intangible Assets9.79M00000000000000
Long-Term Investments000000000000000
Other Non-Current Assets131K1.54M501K604K7.61M1.49M857K050K50K258K15K90K690.05K45.58K
Total Assets1.03B899.42M742.4M490.42M435.09M203.71M131.25M30.26M66.15M52.48M4.26M12.9M8.09M3.67M2.78M
Asset Turnover0.03x0.08x0.00x0.00x0.00x0.01x0.01x0.15x0.13x0.08x0.78x0.20x0.53x1.18x1.58x
Asset Growth %207.18%21.15%51.38%12.72%113.58%55.2%333.73%-54.25%26.04%1132.24%-66.99%59.5%120.25%32.08%-
Total Current Liabilities70.05M70.7M47.87M26.64M33.35M13.64M10.67M10.18M6.73M3.9M4.58M2.47M1.99M1.39M23.6M
Accounts Payable9.3M8.68M2.14M2.24M14.23M2.33M670K1.1M571K906K159K242K255K100K26.66K
Days Payables Outstanding1.97K-----8.64-6.8516.8522.7835.7328.714.613.2
Short-Term Debt00000003.98M2.29M001.1M80K697.06K22.59M
Deferred Revenue (Current)822K367K288K288K288K289K301K03.79M03.38M1.02M076.41K788.19K
Other Current Liabilities019.66M10.74M12.75M4.87M3.75M7.29M674K239K353K1.17M295K1.4M194.31K200K
Current Ratio14.46x12.65x15.43x18.26x12.73x14.68x12.14x2.92x9.71x13.31x0.93x4.75x3.41x1.48x0.07x
Quick Ratio14.46x12.65x15.43x18.26x12.93x14.68x12.14x2.92x9.71x13.31x0.91x4.68x3.32x1.22x0.06x
Cash Conversion Cycle-1.61K---------43.7148.5483.37121.54116.19
Total Non-Current Liabilities377.92M106.56M22.89M21.77M6.68M2.36M544K4.33M8.07M10.07M2.82M24K109K259.35K620.85K
Long-Term Debt242.46M49.94M20.58M20.2M4.64M004.33M8M9.92M2.82M00042.05K
Capital Lease Obligations00000520K000000000
Deferred Tax Liabilities000000000000000
Other Non-Current Liabilities135.46M22.37M2.02M989K1.17M688K544K066K152K024K109K259.35K578.8K
Total Liabilities447.97M177.25M70.76M48.4M40.03M15.99M11.22M14.51M14.8M13.97M4.58M2.49M2.1M1.65M24.22M
Total Debt243.27M50.69M21.09M21.05M5.26M1.04M455K8.3M10.3M9.92M1.04M1.1M80K697.06K22.63M
Net Debt70.41M-161.69M-78.5M-81.78M-150.32M-41.26M-45.44M-16.54M-22.31M-37.52M-2.3M-9.73M-5.04M487.72K22.52M
Debt / Equity0.42x0.07x0.03x0.05x0.01x0.01x0.00x0.53x0.20x0.26x-0.11x0.01x0.34x-
Debt / EBITDA-0.52x--------------
Net Debt / EBITDA-0.15x--------------
Interest Coverage-15.75x-68.24x-87.62x-127.71x-266.23x-26470.00x-79.76x-49.15x-36.46x-68.22x-132.41x-79.34x-6.71x-0.10x-2.53x
Total Equity580.7M722.17M671.64M442.02M395.06M187.72M120.04M15.75M51.34M38.51M-326K10.41M5.99M2.03M-21.44M
Equity Growth %56.71%7.52%51.95%11.89%110.46%56.38%661.95%-69.32%33.33%11912.88%-103.13%73.76%195.63%109.45%-
Book Value per Share5.128.529.899.8812.3115.7533.757.5426.0230.02-0.4519.3039.8410.77-115.23
Total Shareholders' Equity580.7M722.17M671.64M442.02M395.06M187.72M120.04M15.75M51.34M38.51M-326K10.41M5.99M2.03M-21.44M
Common Stock1.14M1.02M810K540K414K239K42K23K308K226K7K106K38K27.91K0
Retained Earnings-1.67B-1.34B-995.86M-725.91M-488.17M-358.3M-278.89M-168.17M-126.3M-93.59M-30.64M-17.97M-6.64M-25.89M-21.44M
Treasury Stock000000000000000
Accumulated OCI-2.2M447K-10K338K-390K-157K-8K0-3K-2.83M0-739K-555K-411.05K-262.74K
Minority Interest000000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Cash runway versus Phase 3 funding

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q3)

Balance Sheet Expanding Through Equity Raises

According to reported quarterly figures, VRDN's total assets climbed from $585.7M in 2024Q2 to $1.0B in 2026Q3 while equity grew to $580.7M, a pattern that points to externally funded expansion rather than internally generated strength.

The rise in total assets appears driven largely by capital raised against an accumulated deficit that reached roughly -$1.7B, indicating the balance sheet is being sustained by financing rather than earnings. Equity remained the dominant funding source throughout the period, which suggests the trajectory is one of dependence on capital markets. Investors should monitor whether the asset base continues to grow faster than the burn rate, as this would signal the company is building durable cash coverage rather than simply deferring dilution.

Cash Buffer Thin Against Phase 3 Spend

As reported in financial statements, VRDN held $172.9M in cash at 2026Q3 against a current ratio of 14.46, a liquidity profile that looks strong on paper but may be inadequate relative to quarterly operating outflows of roughly $90M to $125M.

The high current ratio largely reflects the absence of meaningful current liabilities rather than a surplus of deployable cash, so the ratio overstates true flexibility. Cash on hand appears to cover only a limited number of quarters at recent burn levels, which may indicate that completing the THRIVE programs will require additional capital. This warrants close monitoring of the next financing event and its terms.

Minimal Leverage Keeps Balance Sheet Flexible

Based on EDBL's reported figures, VRDN's total debt of $243.3M at 2026Q3 against equity of $580.7M yields a debt-to-equity ratio of 0.42, a level that is modest but has risen sharply from 0.04 a year earlier.

The step-up in debt during 2026 changes the risk profile, as it introduces a fixed obligation into a company with negative operating cash flow. Leverage remains low in absolute terms, which preserves some flexibility, but the rapid increase suggests the company is now drawing on borrowing alongside equity. The durability of this structure depends on whether debt is used to bridge to a commercial launch or to extend a runway that would otherwise require dilutive equity.

Deferred Revenue Signals Milestone Timing

According to reported figures, VRDN's deferred revenue rose to $36.4M in 2026Q1 and $34.6M in 2025Q4 after sitting near $0.5M through 2025, a pattern that suggests upfront or milestone payments have been received but not yet recognized.

Deferred revenue of this size implies contractual performance obligations that will convert to revenue in future periods, lending some visibility to near-term reported income. However, it is not evidence of recurring demand and is consistent with the lumpy milestone pattern seen across recent quarters. Investors should treat the conversion of this balance as a timing item rather than a durable revenue base.

Accumulated Deficit Masks Equity Quality

Based on reported figures, VRDN's retained earnings of roughly -$1.7B against positive reported equity of $580.7M suggests that book equity reflects capital contributed rather than value created, and stock-based compensation of $30.4M in 2026Q2 adds ongoing dilution pressure.

The gap between accumulated losses and current equity indicates that prior shareholder capital has been consumed by operations, so headline book value may overstate the cushion available to absorb further losses. Recurring stock-based compensation at this scale may mean that a portion of the operating loss is non-cash, yet it still transfers economic value to employees through dilution. Investors should weigh book equity against fully diluted share count and the likelihood of future raises before drawing conclusions about balance sheet strength.

VRDN — Frequently Asked Questions

Quick answers to the most common questions about buying VRDN stock.

What are the total assets of Viridian Therapeutics, Inc. (VRDN)?

As of 2025, Viridian Therapeutics, Inc. (VRDN) had total assets of $899.4M including $894.2M in current assets.

How much debt does Viridian Therapeutics, Inc. (VRDN) have?

Viridian Therapeutics, Inc. (VRDN) carries total debt of $50.7M, offset by $874.7M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Viridian Therapeutics, Inc.?

Viridian Therapeutics, Inc. (VRDN) has total shareholders' equity (book value) of $722.2M ($8.52 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Viridian Therapeutics, Inc.'s current ratio and liquidity?

Viridian Therapeutics, Inc. (VRDN) reported a current ratio of 12.65x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.